All In Biotech

Drug Trial Radar · NCT07307235

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,316 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,316

Planned (sponsor's estimate)

Start

Dec 13, 2025

Primary completion

Jun 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi (China) Investment Co., Ltd
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT). It will compare the efficacy and safety of iGlarLixi versus standard of care in adult T2DM patients with poor glycemic control, who are using 1 to 3 OADs in a real-world clinical practice setting. A total of 1,316 subjects from approximately 40 research centers in China will be randomly assigned in a 1:1 ratio to one of the following treatment groups: Group 1: iGlarLixi for blood glucose control; and Group 2: Standard of care for diabetes (basal insulin or premixed insulin, excluding any GLP-1RA-containing drugs). Considering the substantial difference in intervention methods between the two groups, the study is designed as non-blinded with an open-label approach.

Conditions

  • Type 2 Diabetes

Interventions

  • iGlarLixi (insulin glargine/lixisenatide)Drug

    The investigational drug is iGlarLixi. Participants will receive subcutaneous injections of iGlarLixi with the OAD treatment regimen being appropriately maintained or adjusted as intensification therapy in routine clinical practice.

  • standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)Drug

    The control drug treatment is standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs). Participants will receive standard of care with the OAD treatment regimen being maintained or appropriately adjusted as an intensification treatment during routine clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. hemoglobin A1c (HbA1c) changeTime frame: from baseline to week 24

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of USTC / Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • The First People's Hospital of Huizhou

    Huizhou, Guangdong, China · Recruiting

  • Shenzhen Third People's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Heilongjiang Provincial Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Xinxiang Central Hospital

    Xinxiang, Henan, China · Recruiting

  • Wuhan Fourth Hospital / Wuhan Puai Hospital

    Wuhan, Hubei, China · Recruiting

  • Hunan Provincial People's Hospital / The First Affiliated Hospital of Hunan Normal University

    Changsha, Hunan, China · Recruiting

  • Hengyang Central Hospital

    Hengyang, Hunan, China · Recruiting

  • Affiliated Nanhua Hospital, University of South China

    Hengyang, Hunan, China · Recruiting

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Clinical Hospital of Jilin Academy of Chinese Medicine Sciences

    Changchun, Jilin, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Tenth People's Hospital / Tenth People's Hospital of Tongji University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai East Hospital, Tongji University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pudong New Area Punan Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Minhang Hospital, Fudan University / Central Hospital of Minhang District, Shanghai

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Qingpu District Central Hospital / Qingpu Branch of Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Jiaxing First Hospital

    Jiaxing, Zhejiang, China · Recruiting

  • Ningbo No. 2 Hospital

    Ningbo, Zhejiang, China · Recruiting

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.